preceding RFA to Atezo+Bev for HCC patients
Phase 2
Recruiting
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-jRCT1041200075
- Lead Sponsor
- Yamashita Tatsuya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; previously treated by systemic therapy; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
Exclusion Criteria
refractory ascites or pleural effusion; unsuitable for RFA, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Overall survival, Immunological response, Objective response rate, Tumor control rate, Subsequent therapy, Adverse events